Total Payments
$2.2M
2024 Payments
$165,261
Companies
31
Transactions
1,698
Medicare Patients
2,667
Medicare Billing
$383,488
Payment Breakdown by Category
Other$1.5M (68.4%)
Consulting$327,220 (15.1%)
Travel$275,666 (12.7%)
Research$46,425 (2.1%)
Food & Beverage$34,934 (1.6%)
Education$144.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 540 | 66.0% |
| Consulting Fee | $327,220 | 72 | 15.1% |
| Travel and Lodging | $275,666 | 484 | 12.7% |
| Honoraria | $51,200 | 15 | 2.4% |
| Unspecified | $46,425 | 14 | 2.1% |
| Food and Beverage | $34,934 | 562 | 1.6% |
| Education | $144.19 | 11 | 0.0% |
Payments by Type
General
$2.1M
1,684 transactions
Research
$46,425
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $714,160 | 544 | $0 (2024) |
| Novo Nordisk Inc | $386,752 | 347 | $0 (2024) |
| Amarin Pharma Inc. | $163,641 | 128 | $0 (2021) |
| Kowa Pharmaceuticals America, Inc. | $161,721 | 155 | $0 (2022) |
| Merck Sharp & Dohme LLC | $136,876 | 62 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $132,317 | 94 | $0 (2022) |
| Kowa Research Institute, Inc. | $112,500 | 15 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $98,272 | 73 | $0 (2019) |
| Lilly USA, LLC | $81,226 | 78 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $75,452 | 60 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $165,261 | 159 | Amgen Inc. ($66,993) |
| 2023 | $151,226 | 144 | Amgen Inc. ($102,634) |
| 2022 | $168,825 | 132 | Amgen Inc. ($77,022) |
| 2021 | $223,143 | 158 | Novo Nordisk Inc ($82,947) |
| 2020 | $188,498 | 148 | Amgen Inc. ($76,345) |
| 2019 | $317,491 | 299 | Amgen Inc. ($105,498) |
| 2018 | $429,123 | 305 | Amgen Inc. ($109,488) |
| 2017 | $522,238 | 353 | Amgen Inc. ($108,661) |
All Payment Transactions
1,698 individual payment records from CMS Open Payments — Page 1 of 68
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $4,147.00 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | Cash or cash equivalent | $158.12 | General |
| Category: Cardiology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $31.91 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: RESPIRATORY | ||||||
| 11/20/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: Diabetes | ||||||
| 11/16/2024 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | In-kind items and services | $329.36 | General |
| Category: Cardiology | ||||||
| 11/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $49.70 | General |
| 11/15/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 11/15/2024 | ABBVIE INC. | UBRELVY (Drug), SYNTHROID | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,843.75 | General |
| 11/13/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $1,529.47 | General |
| 11/13/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $83.56 | General |
| 11/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $30.77 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 11/04/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 10/31/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.44 | General |
| 10/21/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 10/17/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 10/14/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Cardiology | ||||||
| 10/02/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Cardiology | ||||||
| 10/02/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Obesity | ||||||
| 09/26/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| "Why is Hypercholesterolemia so Prevalent? A View From Evolutionary Medicine" | Amgen Inc. | $15,112 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $10,964 | 2 |
| CKJX839A1US02 | Novartis Pharmaceuticals Corporation | $8,078 | 3 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $6,358 | 4 |
| DESCARTES Effect Durability | Amgen Inc. | $2,888 | 1 |
| Estimating Rates of CVD Events in the FOURIER-like Population: A Retrospective Cohort Study | Amgen Inc. | $2,087 | 1 |
| A systematic review and network meta-analysis evaluating the clinical effectiveness and safety of t | Amgen Inc. | $529.98 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING THE EFFECTIVENESS OF AN """"INCLISIRAN FIRST"""" IMPLEMENTATION STRATEGY TO USUAL CARE ON LDL CHOLESTEROL (LDL-C) IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND ELEVATED LDL-C (?70 MG/DL) DESPITE RECEIVING MAXIMALLY TOLERATED STATIN THERAPY (VICTORION-INITIATE)""" | Novartis Pharmaceuticals Corporation | $407.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 598 | 1,518 | $251,779 | $91,106 |
| 2022 | 2 | 659 | 1,634 | $254,365 | $95,942 |
| 2021 | 2 | 731 | 1,686 | $229,115 | $116,123 |
| 2020 | 2 | 679 | 1,441 | $180,800 | $80,318 |
Total Patients
2,667
Total Services
6,279
Medicare Billing
$383,488
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 417 | 1,251 | $217,847 | $79,649 | 36.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 164 | 250 | $29,168 | $9,793 | 33.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $4,764 | $1,664 | 34.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 425 | 1,278 | $212,782 | $82,909 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 234 | 356 | $41,583 | $13,033 | 31.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 390 | 970 | $151,406 | $78,475 | 51.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 341 | 716 | $77,709 | $37,647 | 48.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 314 | 666 | $98,562 | $45,448 | 46.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 365 | 775 | $82,238 | $34,870 | 42.4% |
About Dr. Peter Toth, M.D
Dr. Peter Toth, M.D is a Family Medicine healthcare provider based in Sterling, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861572869.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Toth, M.D has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $165,261 received in 2024. These payments were reported across 1,698 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Toth has provided services to 2,667 Medicare beneficiaries, totaling 6,279 services with total Medicare billing of $383,488. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Sterling, IL
- Active Since 10/16/2006
- Last Updated 07/07/2021
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1861572869
Products in Payments
- Repatha (Biological) $707,722
- Ozempic (Drug) $193,809
- Vascepa (Drug) $163,642
- PRALUENT (Drug) $132,236
- PRALUENT ALIROCUMAB INJECTION (Biological) $105,415
- Livalo (Drug) $105,152
- Victoza (Drug) $79,185
- ZEPBOUND (Drug) $51,800
- NEXLIZET (Drug) $46,110
- ENTRESTO (Drug) $40,209
- RYBELSUS (Drug) $27,483
- LEQVIO (Drug) $26,196
- LIPTRUZET (Drug) $25,937
- Rybelsus (Drug) $20,444
- Viekira (Drug) $12,350
- Tresiba (Drug) $10,413
- PRALUENT (Biological) $6,149
- Roszet (Drug) $3,500
- TRULICITY (Drug) $2,200
- CRESTOR (Drug) $2,148
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Sterling
Dr. Charles Gerk, M.d, M.D
Family Medicine — Payments: $37,719
Family Medicine $37,719
Angel Blazquez, M.d, M.D
Family Medicine — Payments: $14,812
Family Medicine $14,812
Svetlana Nakatis, M.d, M.D
Family Medicine — Payments: $7,951
Family Medicine $7,951
Ralph Leon, Md, MD
Family Medicine — Payments: $7,465
Family Medicine $7,465
Ricardo Ferreira Lopez, Md, MD
Family Medicine — Payments: $6,458
Family Medicine $6,458
Phong Dang, M.d, M.D
Family Medicine — Payments: $4,674
Family Medicine $4,674